Evidence map›Paper›PMID 36680092›Full record

ReviewViruses2022

Scratching the Surface Takes a Toll: Immune Recognition of Viral Proteins by Surface Toll-like Receptors.

Alexis A Hatton, Fermin E Guerra

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Anti-interferon armamentarium of human coronaviruses.Cellular and molecular life sciences : CMLS · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alexis A HattonDepartment of Microbiology & Cell Biology, Montana State University, Bozeman, MT 59718, USA.
Fermin E GuerraDepartment of Laboratory Medicine & Pathology, University of Washington, Seattle, WA 98195, USA.
Montana State University · USUniversity of Washington · US

Funding

Defining early anti-viral pathways that dictate a universal TLR2/6-based anti-viral response to conserved viral architectures.F31AI161890 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI HATTON, ALEXIS · 2021 to 2021
$32k
NIAID NIH HHS F31 AI161890
6 · The paper itself

Abstract

Early innate viral recognition by the host is critical for the rapid response and subsequent clearance of an infection. Innate immune cells patrol sites of infection to detect and respond to invading microorganisms including viruses. Surface Toll-like receptors (TLRs) are a group of pattern recognition receptors (PRRs) that can be activated by viruses even before the host cell becomes infected. However, the early activation of surface TLRs by viruses can lead to viral clearance by the host or promote pathogenesis. Thus, a plethora of research has attempted to identify specific viral ligands that bind to surface TLRs and mediate progression of viral infection. Herein, we will discuss the past two decades of research that have identified specific viral proteins recognized by cell surface-associated TLRs, how these viral proteins and host surface TLR interactions affect the host inflammatory response and outcome of infection, and address why controversy remains regarding host surface TLR recognition of viral proteins.

Indexed as

Viral ProteinsVirusesImmunity, InnateReceptors, Pattern RecognitionSignal TransductionToll-Like ReceptorsReceptors, Pattern RecognitionToll-Like ReceptorsViral Proteinscytokinesinnate immunityinterferonsTLR2TLR4TLR agonistTLR antagonistToll-like receptorsviral proteinsviruses

Identifiers

PMID36680092
PMCPMC9863796
OpenAlexW4313244837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.